Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715), an India-based, global specialty generics company with presence in Innovative products, Generics and Consumer Healthcare products, announced on Saturday that it presented its results from a Phase one, multiple ascending-dose study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of GL0034 (Utreglutide) in obese adults in an oral presentation at the 84th Scientific Sessions of the American Diabetes Association (ADA), on 21 June 2024, in Orlando, Florida.
GL0034 (Utreglutide) is a novel differentiated incretin analogue with potent, long-acting agonist activity at the GLP-1 receptor, under evaluation for its potential to provide significant clinical benefits beyond weight loss and gluco-metabolic benefits in individuals with obesity.
The company says that during the study, GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved gluco-metabolic parameters over a four-week treatment period in individuals with obesity, even in the lowest dosing regimen. It demonstrated gluco-metabolic activity and a reduction in lipid levels, including triglycerides, total cholesterol, and non-HDL cholesterol, indicating novel and beneficial impacts on lipid metabolism.
GL0034 is claimed to have demonstrated a favourable tolerability profile, with gastrointestinal (GI) adverse events consistent with those typically seen in the incretin class. The findings indicated the product's potential as a therapeutic option for individuals with obesity, offering not only weight loss, but also improvements in key cardiometabolic biomarkers.
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
Eli Lilly's Kisunla gains UK marketing authorisation for alzheimer's treatment
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
Swedish AI Medical Technologies to begin trial for AI melanoma diagnostic tool
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Trevi Therapeutics finishes enrollment in RCC Phase 2a trial
REGENXBIO reveals positive data for ABBV-RGX-314 in bilateral wet AMD